#United States #Psoriasis #SFA Therapeutics #SFA-002 #Jenkintown

SFA Therapeutics Reports Positive Phase 1b Results for SFA-002

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical firm based in Jenkintown, Pennsylvania, has recently made an important announcement regarding its oral drug candidate, SFA-002. The company revealed promising outcomes from a Phase 1b clinical trial geared towards treating patients suffering from mild-to-moderate psoriasis. The trial's findings indicate significant improvements, making this a notable development in the realm of psoriasis treatment.

The Phase 1b trial aimed to evaluate not only the safety of SFA-002 but also its efficacy in treating psoriasis symptoms. Impressively, the drug met its primary endpoint for safety, demonstrating a clean safety profile with no treatment-related adverse events reported. This is a critical result as safety is a major concern in pharmaceutical treatments for chronic conditions. Furthermore, no rebound effects were noted during the treatment period, which is particularly promising for those with ongoing management needs.

In terms of efficacy, the trial revealed that subjects taking SFA-002 presented remarkable enhancements in their Psoriasis Area and Severity Index (PASI) and Investigator Global Assessment (IGA) scores. These two metrics are crucial for measuring the severity and extent of psoriasis, providing clear evidence that the drug is effective in reducing symptoms.

Dr. Stefan C. Weiss, the Chief Medical Officer at SFA Therapeutics, expressed optimism based on the results from Cohort 2 of the Phase 1b trial. He stated, “We are confident that SFA-002 will have a significant impact in alleviating psoriasis symptoms in our forthcoming Phase 2 clinical trial.”

Ira Spector, the CEO of SFA Therapeutics, emphasized the importance of SFA-002 in addressing the needs of mild-to-moderate psoriasis patients, who constitute over 80% of all plaque psoriasis cases. He noted that current oral treatment options for this group are limited and believes SFA-002’s oral administration combined with its targeted, non-immunosuppressive approach fills this critical gap in the market.

SFA-002 has the potential to not only change the treatment landscape for psoriasis by providing a safer and more effective oral option but also represents a broader approach for treating inflammatory and autoimmune diseases. SFA Therapeutics has built its foundation on cutting-edge research licensed from Temple University, which indicates a commitment to developing innovative solutions for chronic conditions.

As SFA Therapeutics moves forward with its research, it is poised to investigate Cohort 2's formulation of SFA-002 in a larger Phase 2 clinical trial, further validating its initial findings and supporting its future application in clinical settings.

To learn more about SFA Therapeutics and its innovative approach to treating chronic inflammatory and autoimmune diseases, visit www.sfatherapeutics.com.